$CVM

CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, has closed a best-efforts public offering, raising approximately $7.2 million in gross proceeds from the sale of 6,000,000 shares of common stock at $1.20 per share. The company plans to use these funds for the continued development of its Multikine treatment, general corporate purposes, and working capital. ThinkEquity acted as the sole placement agent for the offering.